2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118037
    VUF10132 1037732-88-9 98%
    VUF10132 is a non-peptide CXCR3 receptor antagonist with anti-inflammatory activity, inhibiting diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis. VUF10132 has high affinity for the human CXCR3 receptor but slightly lower affinity for the murine CXCR3 receptor. Additionally, VUF10132 exhibits inverse agonist properties at the CXCR3 receptor.
    VUF10132
  • HY-118047
    CI 972 anhydrous 115787-68-3 98%
    CI 972 anhydrous is a potent, orally active, and competitive inhibitor of purine nucleoside phosphorylase (PNP) (Ki=0.83 μM) under development as a T cell-selective immunosuppressive agent.
    CI 972 anhydrous
  • HY-118055
    15-Deoxy-Δ12,14-prostaglandin A2 112839-31-3 98%
    15-Deoxy-Δ12,14-prostaglandin A2 is a synthetic analog of PGA2.
    15-Deoxy-Δ12,14-prostaglandin A2
  • HY-118057
    L-739594 156879-13-9 98%
    L-739594 is a HIV-1 protease inhibitor, with an IC50 of 1.8 nM.
    L-739594
  • HY-118084
    LS-104 368836-72-0 98%
    LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies.
    LS-104
  • HY-118101
    15-Deoxy-Δ12,14-prostaglandin A1 573951-20-9 98%
    15-Deoxy-Δ12,14-prostaglandin A1 is a deoxyanalog of prostaglandins that inhibits NF-κB signaling and induces apoptosis. 15-Deoxy-Δ12,14-prostaglandin A1 inhibits TNF-α-induced upregulation of inflammatory endothelial cell adhesion molecule (CAM) and avoids monocyte arrest.
    15-Deoxy-Δ12,14-prostaglandin A1
  • HY-118160
    PPM-18 65240-86-0 98%
    PPM-18 (NSC 73233), a potent anti-inflammatory agent, inhibits nitric oxide synthase expression. PPM-18 is a potent inhibitor of iNOS expression by blocking the binding of NF-κB to promoter. PPM-18, an analog of Vitamin K, induces autophagy and apoptosis in bladder cancer cells through ROS and AMPK signaling pathways.
    PPM-18
  • HY-118167
    Monoethylglycinexylidide 7728-40-7 98%
    Monoethylglycinexylidide is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver[1].
    Monoethylglycinexylidide
  • HY-118180
    CAY10595 916047-16-0 98%
    CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM.
    CAY10595
  • HY-118197
    L-669083 130007-52-2 98%
    L-669083 is a leukotriene biosynthesis inhibitor whose structure is based on a mixture of indole and quinoline. In this study, a potent radioiodinated photoaffinity analog of L-689,037, [125I] L-691,678, was developed and characterized for immunoprecipitation studies showing that the quindole series of leukotriene biosynthesis inhibitors directly interact with FLAP. In addition, the results showed that MK-886, L-674,573, and L-689,037 competed with [125I] L-691,678 and [125I] L-669083 for binding to FLAP in a concentration-dependent manner, indicating that these three leukotriene biosynthesis inhibitors share a binding site on FLAP, further demonstrating that FLAP is a suitable target for structurally diverse leukotriene biosynthesis inhibitors.
    L-669083
  • HY-118239
    Re 80 116193-60-3 98%
    Re 80 is an anti-angiogenic agent and is a synthetic retinoid.
    Re 80
  • HY-118299
    JYL 1511 623166-14-3 98%
    JYL 1511 is a partial agonist of vanilloid receptor VR1.
    JYL 1511
  • HY-118316
    GSK223 899758-61-3 98%
    GSK223 is a quinazolinone NOD1 pathway inhibitor with potential anti-inflammatory activity. GSK223 can selectively inhibit IL-8 release under iE-DAP stimulation without affecting IL-8 secretion caused by TNF receptor, TLR2 or NOD2 agonists. GSK223 does not directly inhibit RIP2 kinase activity.
    GSK223
  • HY-118336
    VUF10497 1080623-12-6 98%
    VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity.
    VUF10497
  • HY-118408
    D-4418 257892-34-5 98%
    D-4418 serves as a PDE4 inhibitor and is under development as a new anti-inflammatory treatment, primarily targeting asthma and chronic obstructive pulmonary disease.
    D-4418
  • HY-118423
    SJ-3366 195720-26-4 98%
    SJ-3366 (IQP-0410) is a potent inhibitor of HIV nonnucleoside reverse transcriptase. SJ-3366 (IQP-0410) inhibits HIV at sub-nanomolar concentrations primarily through a typical non-nucleoside mechanism.
    SJ-3366
  • HY-118489
    L644711 81997-33-3 98%
    L644711 is an anion transport inhibitor that reduces cell swelling by inhibiting potassium-activated D-aspartate release in astrocytes. L644711 can be used in the study of brain injury and neuroprotection.
    L644711
  • HY-118506
    BRP-7 612046-20-5 98%
    BRP-7 is a 5-lipoxygenase activating protein (FLAP) inhibitor. BRP-7 inhibits the co-localization of 5-lipoxygenase (5-LOX) and FLAP by targeting FLAP, thereby blocking the transfer of arachidonic acid (AA) to 5-LOX and suppressing the production of leukotrienes (LTs) (IC₅₀ = 0.15 μM). BRP-7 does not inhibit cyclooxygenase (COX-1/COX-2) or microsomal prostaglandin E₂ synthase-1 (mPGES-1), and does not affect cell viability or AA release. BRP-7 exhibits significant anti-inflammatory effects in rat pleurisy and mouse peritonitis models. BRP-7 can be used for the study of inflammatory diseases.
    BRP-7
  • HY-118546
    JNJ-17156516 649551-06-4 98%
    JNJ-17156516 is an orally active, potent, and selective cholecystokinin (CCK)1-receptor antagonist.
    JNJ-17156516
  • HY-118584
    Ro 12-7310 65316-65-6 98%
    Ro 12-7310 is a synthetic retinoid, and can inhibit arachidonic acid release.
    Ro 12-7310
Cat. No. Product Name / Synonyms Application Reactivity